logo
  

Why Spero Therapeutics Stock Falling In Pre-market?

Spero Therapeutics, Inc. (SPRO) said the company will immediately defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting with the FDA regarding New Drug Application for tebipenem HBr. The discussion suggested that the data package may be insufficient to support approval during this review cycle, the company noted.

Spero also announced that it is undertaking a reduction in workforce by approximately 75% and a restructuring of operations to reduce operating costs and reallocate resources towards the clinical development programs of SPR720 and SPR206.

Shares of Spero Therapeutics were down 70% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT